<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001942670</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>11/16/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001824893</issuerCik>
        <issuerName>Surrozen, Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>86889P208</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">171 Oyster Point Blvd, Suite 400</street1>
          <city xmlns="http://www.sec.gov/edgar/common">South San Francisco</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">94080</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>AI Biotechnology LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>2212556</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>2212556</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2212556</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.9</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Rows 6, 8 and 9: The total number of shares of common stock, par value $0.0001 per share (the "Common Stock"), of Surrozen, Inc. (the "Issuer") reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology LLC ("AI Biotechnology") and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker (as defined in Item 4), but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.

Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in its November 2026 underwritten public offering (the "Offering"), as reported in the Issuer's Current Report on Form 8-K filed with the SEC on November 16, 2026, and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Access Industries Holdings LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>2212556</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>2212556</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2212556</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.9</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.

Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Access Industries Management, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>2212556</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>2212556</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2212556</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.9</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.

Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Len Blavatnik</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>2212556</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>2212556</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2212556</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.9</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker.

Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Surrozen, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>171 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>AI Biotechnology LLC

Access Industries Holdings LLC ("AIH")

Access Industries Management, LLC ("AIM")

Len Blavatnik</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Each of AI Biotechnology, AIH and AIM is a limited liability company organized under the laws of the State of Delaware.
Mr. Blavatnik is a citizen of the United States of America.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See the responses to Item 9 on the attached cover pages.</amountBeneficiallyOwned>
        <classPercent>See the responses to Item 11 of the attached cover pages. The percentages reported in Item 11 of the attached cover pages are based upon the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See the responses to Item 5 on the attached cover pages.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See the responses to Item 6 on the attached cover pages.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See the responses to Item 7 on the attached cover pages.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See the responses to Item 8 on the attached cover pages.

AI Biotechnology (a) directly holds 1,021,043 shares of Common Stock, including 252,605 shares acquired in the Offering, and (b) directly holds (i) Pre-funded Warrants exercisable at any time at a price per share of $0.0001 for an aggregate of 754,500 shares of Common Stock and (ii) Series E Warrants exercisable at any time at an exercise price of $11.54 for an aggregate of 757,500 shares of Common Stock, of which an aggregate of 1,191,513 shares of Common Stock are treated as beneficially owned after giving effect to the Beneficial Ownership Blocker (defined below).

The Pre-funded Warrants and the Series E Warrants held directly, or that may be acquired within 60 days of this filing, by AI Biotechnology may not be exercised if the aggregate number of shares of Common Stock beneficially owned by AI Biotechnology (together with its affiliates) immediately following such exercise would exceed 9.99% of the outstanding shares of Common Stock, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AI Biotechnology may increase or decrease the foregoing beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (the "Beneficial Ownership Blocker").

The shares of Common Stock that may be deemed to be beneficially owned as of the date of this filing by AI Biotechnology may also be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH, and (iii) AIH directly controls all of the outstanding voting interests in in AI Biotechnology. Each of the Reporting Persons (other than AI Biotechnology) and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>AI Biotechnology LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Alejandro Moreno</signature>
        <title>By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno</title>
        <date>11/20/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Access Industries Holdings LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Alejandro Moreno</signature>
        <title>By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno</title>
        <date>11/20/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Access Industries Management, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Alejandro Moreno</signature>
        <title>Executive Vice President/Alejandro Moreno</title>
        <date>11/20/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Len Blavatnik</reportingPersonName>
      <signatureDetails>
        <signature>*/s/Alejandro Moreno</signature>
        <title>By: Alejandro Moreno/Attorney-in-Fact</title>
        <date>11/20/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>* The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.</signatureComments>
  </formData>
</edgarSubmission>
